{
    "2021-04-16": [
        [
            {
                "time": "",
                "original_text": "持续亏损、依靠外部融资 益方生物商业化困局待解 亏损",
                "features": {
                    "keywords": [
                        "持续亏损",
                        "外部融资",
                        "益方生物",
                        "商业化困局"
                    ],
                    "sentiment_score": -0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "持续亏损、依靠外部融资 商业化困局下IPO能否解益方生物“燃眉之急” 亏损",
                "features": {
                    "keywords": [
                        "持续亏损",
                        "外部融资",
                        "商业化困局",
                        "IPO",
                        "益方生物"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}